Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Dugan

Hematology & Oncology Indianapolis, IN Medical Doctor

NPI 1437263399 CMS profile 20422

8111 S Emerson Ave, #105, Indianapolis, IN 46237

Open in the dashboard

General payments

$236,221

261 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Dugan of Indianapolis, IN is reported in the CMS Open Payments database as having received $236,221 across 261 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $52 2
2024 General $58 2
2023 General $55,034 51
2022 General $36,731 46
2021 General $28,149 34
2020 General $42,311 38
2019 General $73,886 88

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Dugan
  • Hematology & Oncology median
  • Middle half of Hematology & Oncology
  • National median

In program year 2025, general payments to Michael Dugan were reported at $52. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.

Show as a table
Year Michael Dugan Hematology & Oncology median Middle half National median
2019 $73,886 $529 $121–$2,516 $163
2020 $42,311 $339 $82–$2,213 $114
2021 $28,149 $263 $49–$1,965 $132
2022 $36,731 $416 $103–$2,395 $149
2023 $55,034 $542 $125–$2,646 $160
2024 $58 $692 $141–$3,008 $164
2025 $52 $683 $143–$3,154 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Celgene Corporation $124,944 120 payments
  2. E.R. Squibb & Sons, L.L.C. $91,199 90 payments
  3. Jazz Pharmaceuticals Inc. $10,335 18 payments
  4. Pfizer Inc. $4,033 8 payments
  5. Janssen Biotech, Inc. $3,484 8 payments
  6. Adaptive Biotechnologies Corporation $1,511 2 payments
  7. Janssen Scientific Affairs, LLC $259 4 payments
  8. Amgen Inc. $138 2 payments
  9. Astellas Pharma US Inc $105 1 payment
  10. Seattle Genetics, Inc. $46 1 payment
  11. Other $166 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $182,408 60 payments
  2. Travel and Lodging $33,051 102 payments
  3. Consulting Fee $14,852 9 payments
  4. Food and Beverage $5,312 85 payments
  5. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $565 1 payment
  6. Education $32 4 payments
Products named General payments · program years 2019–2025
  1. Pomalyst $80,388 84 payments
  2. Revlimid Hematology / Oncology $48,086 46 payments
  3. Revlimid Hematology $15,680 11 payments
  4. INREBIC Hematology $14,762 16 payments
  5. ONUREG $13,992 10 payments
  6. ABECMA $11,708 14 payments
  7. Inrebic Myelofibrosis $7,775 6 payments
  8. MYLOTARG $4,033 8 payments
  9. DARZALEX $3,604 9 payments
  10. VYXEOS $3,589 7 payments
  11. Other $2,222 24 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

261 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hematology & Oncology in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record